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ABSTRACT 
Objective: to compare the predictive accuracy of the original and recalibrated 
Framingham risk function on current morbidity from coronary heart disease (CHD) and 
mortality data from the Swiss population. 
Methods: data from the CoLaus study, a cross-sectional, population-based study 
conducted between 2003 and 2006 on 5,773 participants aged 35-74 without CHD were 
used to recalibrate the Framingham risk function. The predicted number of events from 
each risk function were compared with those issued from local MONICA incidence rates 
and official mortality data from Switzerland. 
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Results: with the original risk function, 57.3%, 21.2%, 16.4% and 5.1% of men and 
94.9%, 3.8%, 1.2% and 0.1% of women were at very low (<6%), low (6-10%), 
intermediate (10-20%) and high (>20%) risk, respectively. With the recalibrated risk 
function, the corresponding values were 84.7%, 10.3%, 4.3% and 0.6% in men and 
99.5%, 0.4%, 0.0% and 0.1% in women, respectively. The number of CHD events over 
10 years predicted by the original Framingham risk function was 2-3 fold higher than 
predicted by mortality + case fatality or by MONICA incidence rates (men: 191 vs. 92 
and 51 events, respectively). The recalibrated risk function provided more reasonable 
estimates, albeit slightly overestimated (92 events, 5–95th percentile: 26 – 223 events); 
sensitivity analyses showed that the magnitude of the overestimation was between 0.4 
and 2.2 in men, and 0.7 and 3.3 in women.  
Conclusion: the recalibrated Framingham risk function provides a reasonable alternative 
to assess CHD risk in men, but not in women. 
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INTRODUCTION 
Cardiovascular disease is the worldwide leading cause of death [1], and its burden 
is expected to increase by 2030 [2]. Current guidelines indicate that coronary heart 
disease (CHD) prevention should rely on absolute risk assessment and not on individual 
risk factors [1,3-9]. To facilitate absolute CHD risk calculation, several risk functions and 
charts have been developed, based on prospective data collected in different countries 
and settings [10-13]. To enable adequate and cost-effective treatment, the available risk 
functions must provide reliable estimates of CHD risk within a given population. Since 
CHD morbidity and mortality vary considerably by country or ethnicity [14-16], 
population-specific equations have been proposed [17-19]. Nevertheless, several studies 
have shown that even risk functions developed in a given country might not be fully 
usable “as is” in a neighbouring country [20]. 
Of particular concern is the fact that most risk functions have been developed in 
countries with high CHD incidence. When applied to populations with a lower CHD risk, 
those functions might considerably overestimate CHD risk. For instance, the widely used 
Framingham risk function [7,21] has been shown to adequately predict CHD risk in the 
United States, Australia, and New Zealand, but to overestimate CHD risk if directly 
applied to populations with low CHD levels, including many European populations [18-
20,22-27]. Overestimation of the risk leads to unnecessary anxiety and prescription of 
costly medicines to the subject [28,29] with considerable inadequate resource allocation, 
while risk underestimation leads to undertreatment of subjects who would benefit from 
risk reduction. Further, the risk functions are not interchangeable as they evaluate 
different CHD risks (fatal and/or nonfatal cardiovascular events; with or without angina) 
[10-13]. 
In order to compute absolute CHD risk for a specific population, recalibration of 
the risk functions has been suggested [11,18,19]. Recalibration is based on the 
assumption that the effect of a given cardiovascular risk factor on CHD morbidity and 
mortality is constant across populations [30,31], and that only the classification of an 
individual relative to the population average influences individual risk. Thus, recalibration 
is made by replacing the initial population means by the means of the population to 
which the equation is recalibrated, using the same coefficients [17-19]. Indeed, 
recalibration of the original Framingham risk function was shown to correctly predict CHD 
risk in populations characterized by a low incidence of CHD such as Spain [18] or China 
[19].  
CHD mortality rates are low in Switzerland [14], with a favorable declining trend 
during the last decade [32]. However, it is currently unknown whether the available risk 
functions adequately predict ten-year CHD risk in Switzerland. Thus, our aim was to 
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compare the results of the Framingham CHD risk function in its original form [13] and 
after recalibration on the Swiss population with the official national CHD mortality rates in 
Switzerland and the predicted number of events based on incidence rates from the Vaud-
Fribourg MONICA study [14]. 
SUBJECTS AND METHODS 
Study population 
The CoLaus Study was approved by the Institutional Ethic’s Committee of the 
University of Lausanne and took place in the city of Lausanne in Switzerland, a town of 
117,161 inhabitants, of which 79,420 are of a Swiss nationality1. The CoLaus Study is a 
cross-sectional study aimed at assessing the prevalence and deciphering the molecular 
determinants of cardiovascular risk factors in the Caucasian population of Lausanne, 
Switzerland. 
The sampling procedure of the CoLaus Study has been described previously [33]. 
Briefly, the complete list of Lausanne inhabitants aged 35-75 years (n=56,694) was 
provided by the population registry of the city. A simple, non-stratified random sample of 
35% of the overall population was drawn. The following inclusion criteria were applied: a) 
written informed consent; b) aged 35-75 years; c) willingness to take part in the 
examination and donate blood sample and d) Caucasian origin. The CoLaus study 
included only Caucasians to reduce heterogeneity for genetic analyses. Caucasian origin 
was defined as having both Caucasian parents and grandparents. 
Assessment process 
Recruitment began in June 2003 and ended in May 2006. All participants attended 
the outpatient clinic of the University Hospital of Lausanne in the morning after an 
overnight fast. Data were collected by trained field interviewers in an single visit lasting 
about 60 minutes. The first questionnaire mailed with the appointment’s letter and 
completed by the participant prior to the morning visit was reviewed and a second 
questionnaire was applied by interview prior to clinical measurements and blood 
collection. 
Clinical data 
Blood pressure and heart rate were measured three times on the left arm after at 
least 10 minutes rest in the seated position using a clinically validated automated 
oscillometric sphygmomanometer (Omron® HEM-907, Matsusaka, Japan) [34], using an 
appropriately sized cuff. The average of the last two readings was used for analyses. 
Biological data 
Venous blood samples (50 ml) were drawn in the fasting state. All measurements 
were conducted using a Modular P apparatus (Roche Diagnostics, Switzerland) by the 
Clinical Laboratory of the Centre Hospitalier Universitaire Vaudois (CHUV). Total 
cholesterol was assessed by enzymatic method (maximum inter-batch CV: 1.6%; 
maximum intra-batch CV: 1.7%); HDL-cholesterol was also assessed by the same 
enzymatic method after precipitation of apolipoprotein B carrying lipoproteins by 
polyethylene-glycol + cyclodextrin (maximum inter-batch CV: 3.6%; maximum intra-
batch CV: 0.9%); glucose was assessed by glucose dehydrogenase (maximum inter-
batch CV: 2.1% %; maximum intra-batch CV: 1.0%). In order to comply with the 
original Framingham risk equation [13], diabetes was defined as fasting plasma glucose 
≥7.8 mmol/L and/or presence of oral hypoglycaemic or insulin treatment. 
Statistical analyses 
Statistical analyses were conducted using Stata v9.2 for Windows (Stata Corp, 
Texas, USA). Ten year CHD risks were computed using the original [13] and recalibrated 
Framingham risk functions. To ensure comparability with the established Framingham 
function, hypertension was defined according to the Fifth Joint National Committee on 
Hypertension [35] and the cut-points for total and HDL cholesterol were from the 
                                                 
1 http://www.lausanne.ch/view.asp?DomId=63584 data for 2003 ; site assessed February 2007 
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National Cholesterol Education Program Adult Treatment Panel II (ATP-II) [36]. Similar to 
the Framingham approach [13], treatments for high blood pressure and high blood 
cholesterol were not included in the formulations. As relative comparisons of risks have 
been shown to be valid using recalibration in diverse populations [17-19], we 
recalibrated the Framingham equations by replacing the mean of each risk factor used in 
the original equation by the gender-specific mean derived from the CoLaus study, under 
the assumption that the effects of the risk factors are reasonably universal [30,31]. 
Subjects were further classified into very low risk (<6%), low risk (6 – 10%), 
intermediate risk (10 – 20%) and high risk (>20%) according to international 
recommendations [8,9].  
The Framingham risk functions described above (original and recalibrated) were then 
used to calculate CHD risk in the CoLaus sample. For each gender and age group, the 
mean risk and the corresponding 5th and 95th percentiles were obtained. The computed 
10-year rates were then applied to the CoLaus subjects in order to estimate the mean 
number and 95% confidence interval of fatal and non-fatal CHD events. Gender- and age 
group-specific CHD mortality rates (ICD-10 codes I21 to I23, corresponding to “acute 
myocardial infarction”, “subsequent myocardial infarction” and “certain current 
complications following acute myocardial infarction”, respectively) for 2003 were 
obtained from the Swiss Statistical Bureau (Office Fédéral de la Statistique). In men, 
fatal and non-fatal CHD events were further assessed using age-specific first event 
incidence rates from the MONICA study (corresponding to MONICA definition 1 for 
coronary events) obtained separately for two regions (cantons Vaud + Fribourg and 
canton Tessin) [37] and in-hospital MI mortality rates for year 2003 from the Swiss AMIS 
plus register [38]. MONICA definition 1 for coronary events included non-fatal events 
satisfying the criteria for definite myocardial infarction, and fatal events classified as 
definite, possible, and unclassifiable coronary deaths, the latter comprising mainly 
sudden deaths with no available diagnostic information [14]. Incidence rates were not 
available for women, as the Swiss MONICA project did not collect outcome data for 
women [14]. Since about half of CHD deaths occur before reaching hospital [39-41], the 
actual Swiss case-fatality rate for 2003 (about 6% for all patients) [38] was doubled and 
a more conservative value of 12% was used to compute the number of fatal and non-
fatal CHD events, defined as: 
number of CHD events = number of fatal events / MI case-fatality rate.  
A sensitivity analysis was also conducted, in which each rate was independently 
modified; for instance, case-fatality rates were modified while holding mortality rates 
constant (the 2003 age- and gender-specific mortality rates were used); similarly, 
mortality rates were modified holding the case-fatality rates constant at 18% [42]. 
Descriptive results were expressed as number of subjects and (percentage) or as mean ± 
standard deviation. Statistical analysis was conducted using Chi-square or Student’s t-
test. Statistical significance was considered for two-tailed p<0.05. 
RESULTS 
Sampling results and sample characteristics 
Of the initial 19,830 subjects sampled, 15,109 (76%) responses were obtained. Of 
the responses, 6,189 (41%) subjects refused, 799 (5%) were considered as non-eligible 
and 8,121 accepted (57% of the eligible responders, 54% of the responders and 41% of 
the sampled population). Of the 8,121 subjects who agreed to participate, the first 6,738 
were invited to attend the clinic and completed the examination; of them 549 (8.1%) 
were not of Caucasian ethnicity and were excluded and one withdraw after consent 
because of personal reasons. It should be noted that since the number of subjects who 
agreed to participate (8,121) was higher than the number of subjects initially planned for 
the CoLaus study (6,000), then 1,383 subjects were not assessed although actually they 
were willing to participate. Thus, the final CoLaus study (n=6,188 participants) 
represents 43% of the eligible responders, 41% of the responders and 31% of the 
sampled population. Finally, of the 6,188 subjects, 397 were not included in the present 
analysis because of previous history of cardiovascular disease at baseline, defined as a 
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self-reported diagnosis of CHD (angina, prior myocardial infarction, PTCA, or CABG), 
stroke, or peripheral arterial disease. Another 18 subjects were not considered because 
of missing data for the calculation of the CHD risks. The characteristics of the remaining 
5,773 subjects (3,074 women and 2,699 men) are summarized in Table 1. Women were 
significantly older and presented with higher HDL cholesterol levels than men, while men 
were more frequently smokers, presented more frequently with diabetes and had higher 
SBP and DBP levels than women. No differences were found regarding total cholesterol 
levels. 
Results of the Framingham risk function 
The mean and 5 – 95th percentiles for CHD risk and the CHD risk categories 
according to gender are summarized in Table 1. Men had significantly higher risk than 
women, and the recalibrated function gave mean risks that were about half of those 
estimated by the original equation. Very few women were categorized as presenting with 
intermediate/high risk using the original equation, and this number further decreased 
with the recalibrated function; also, 21% of men presented with intermediate/high risk 
using the original equation, and this percentage decreased to slightly less than 5% using 
the recalibrated equation (Table 1). 
The number of predicted events over 10 years as estimated from the original and 
the recalibrated Framingham risk equations according to gender and age group are 
presented in Table 2 and in Figure 1. Since no age-specific incidence rates for men 
were available from MONICA, only the overall estimated events for the 35-64 age group 
are presented. In both genders, the original Framingham risk function overestimated the 
number of events by two-fold, with the notable exception of age group 65-74, where the 
estimated number of events was close to the projected ones. Conversely, the 
recalibrated Framingham risk function provided somewhat better estimates, but 
underestimated the number of events in age group 65-74 years (Figure 1). In both 
genders, the recalibrated Framingham risk function provided overall estimates closer to 
those predicted by mortality and case-fatality rates or by the MONICA incidence rates. 
The numbers for the original Framingham equation were considerably higher than those 
obtained for the recalibrated Framingham equation or from data on mortality + case-
fatality rates: in women, the number of events was 54.1, 23.8 and 32.2, respectively; 
the corresponding numbers for men were 190.6, 62.3 and 83.0; using incidence data 
from the MONICA study led to 51 (for Vaud + Fribourg) to 68 (for canton Tessin) events 
in men, values within the range of the estimations obtained using the recalibrated 
Framingham equation. 
Since CHD events were estimated using age- and gender-specific mortality + 
case-fatality rates, a sensitivity analysis was conducted, in which each rate was 
independently modified. Using the 2003 CHD mortality rates, the recalibrated 
Framingham risk function overestimated the total number of events for any case-fatality 
rate over 11% in men and 17% in women. Conversely, for a constant case-fatality rate 
of 18%, the recalibrated Framingham risk function overestimated the total number of 
events for mortality rates 10% higher than those reported in 2003 for women and 65% 
higher in men (Table 3). The ratio (number of events by the recalibrated Framingham 
function)/(number of events issued from mortality + case fatality rates) was between 0.5 
and 2.0 (not shown), except for age group 35-44 years for which the ratio were between 
0.7 and 6. Finally, increasing case-fatality rates over 44% led to an overestimation of the 
number of events by the recalibrated risk function (not shown). 
DISCUSSION 
In agreement with previous studies performed in populations with relatively low 
CHD risk [18-20,22,24], the original Framingham risk function overestimated by a factor 
of 2 to 3 the number of events predicted by the MONICA incidence rates or by the joint 
use of mortality and case-fatality rates. The recalibrated risk function provided estimates 
that better matched but still slightly overestimated the projected number of events, 
except for a large overestimation in women aged over 65. A possible explanation is the 
fact that the Swiss case-fatality rate used to compute the number of cases was only 
12%, which is very low compared to the literature [43,44] and might have artificially 
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inflated the number of events. Indeed, increasing case-fatality rates to 25%, a more 
reasonable [43] estimate, led to more consistent results (Table III), while increasing 
case-fatality rates to 44% as reported by others [44] led to an overestimation of the 
number of events. Still, sensitivity analysis showed that this overestimation was 
relatively small within a reasonable range of mortality and case-fatality rates, as 
compared to the original Framingham function, which considerably overestimates the 
number of CHD events in the Swiss population, whereas the recalibrated risk function 
might provide better, albeit slightly overestimated, risks. The underestimation of the 
number of events among participants aged over 64 years might be related to the fact 
that a single case-fatality rate was applied for all age groups, and it is known that case-
fatality tends to increase with age [39,42]. Indeed, as indicated in table III, applying a 
20% case-fatality rate to subjects aged over 64 years as reported in the literature [42] 
led to a slight overestimation of the number of events by the recalibrated Framingham 
function. 
European guidelines recommend the use of the EU-SCORE, a risk score based on 
data from European cohort studies which estimates of ten-year risk of fatal 
cardiovascular disease (stroke + coronary heart disease + sudden death) [11]. Still, the 
SCORE function has not yet been validated in the Swiss population and it is not possible 
to compare its predictive accuracy relative to the Framingham risk function as those two 
risk functions do not estimate the same risk (cardiovascular mortality for SCORE, fatal 
and nonfatal CHD events for Framingham).  
This study has several limitations that must be accounted for. First, no prospective 
data were available in Switzerland for women. Thus, we used official mortality data and 
case-fatality rates to compute the number of events for comparison with the results from 
the risk functions. This type of approach has been used in the past by others [45,46] for 
recalibration of risk equations.  We rely here on the high quality of coding the cause of 
death in Switzerland, especially for persons aged less than 80 as previously published 
[32,47], and which have shown a very good agreement between official CHD deaths 
codes and CHD deaths reported by the MONICA investigators [14]. Although this 
methodology might lead to less precise results, the sensitivity analyses showed that, for 
the original Framingham risk function, the predicted risks were too high to be compatible 
with the current mortality and case-fatality rates. By contrast, the results from the 
recalibrated Framingham risk function were actually compatible with, or slightly 
overestimated within a reasonable range, observed mortality and case-fatality rates. The 
CoLaus study might not be fully representative of the overall Swiss population, as it was 
drawn from a single Canton (Vaud) and only included Caucasian subjects, i.e. the 
majority of the population of Switzerland, and questions might arise whether the genetic 
mix of Caucasians in Lausanne is representative of the whole country. Still, a 
considerable proportion of the Lausanne population is non-Swiss or comes from other 
cantons, including Italian and Germanic origin: in 2006, out of the 128,231 Lausanne 
inhabitants, 49,330  (38%) were non-Swiss, 38,513 (30%) came from other cantons, 
and only 40,388 subjects (32%) were actually from the Vaud canton 1. We thus believe 
that the genetic mix of the CoLaus sample is relatively large and that the results may be 
extrapolated with reasonable confidence to the Swiss population. A sampling bias might 
also have occurred, participants presenting with a better health (and thus a lower risk) 
than non-participants; this could partly explain the underestimation of the number of 
events by the recalibrated Framingham equation in participants aged over 64 years. 
Unfortunately, no health data regarding non-participants could be collected. Still, in the 
absence of a representative sample for the whole Swiss population, these currently 
represent the best estimates available for the calibration of the Framingham risk 
function.  
The strengths of our study were its population-based design, with limited 
exclusion criteria and a large range of age, and the availability of all traditional 
                                                 
1 http://www.lausanne.ch/view.asp?docId=22884&domId=63584&language=F, site assessed November 19, 
2007 
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cardiovascular risk factors. Finally, the CoLaus study will enable better estimates of the 
incidence of CHD and thus a better recalibration of the risk scores. 
In summary, our population-based study indicates that the original Framingham 
risk function overestimates the risk of CHD events in the Swiss population by a 
magnitude of 2 to 3. The recalibrated risk function might provide a reasonable alternative 
for the calculation of 10-year CHD risk in men, while it tends to underestimate risk in 
women aged over 65. When prospective data will be available in Switzerland, its validity 
should be further assessed using longitudinal data. 
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TABLES 
Table I: sample characteristics and ten-year CHD risks according to the risk function 
used, by gender. 
 Women (n=3,074) Men (n=2,699) test 
Age (years) 53.1 ± 10.6 51.8 ± 10.5 4.70 *** 
Diabetes (%) 86 (2.8) 178 (6.6) 47.49 *** 
Smokers (%) 776 (25.2) 793 (29.4) 12.48 *** 
SBP (mm Hg) 124 ± 18 132 ± 16 15.94 *** 
DBP (mm Hg) 78 ± 11 81 ± 11 13.72 *** 
Total cholesterol (mg/dL) 217 ± 40 217 ± 40 0.63 NS 
HDL cholesterol (mg/dL) 70 ± 16 56 ± 14 34.89 *** 
All CHD events    
Framingham, original    
Mean risk 1.8 (0.1 – 6.1) 7.1 (1.1 – 20.2) 2270 *** 
Risk categories (%)    
Very low (<6%) 2918 (94.9) 1547 (57.3)  
Low (6 – 10%) 117 (3.8) 572 (21.2) 1177 *** 
Intermediate (10 – 20%) 37 (1.2) 442 (16.4)  
High (>20%) 2 (0.1) 138 (5.1)  
Framingham, recalibrated    
Mean risk 0.8 (0.1 – 2.7) 3.4 (0.5 – 9.9) 2415 *** 
Risk categories (%)    
Very low (<6%) 3059 (99.5) 2287 (84.7)  
Low (6 – 10%) 13 (0.4) 278 (10.3) 459 *** 
Intermediate (10 – 20%) 0 (0.0) 117 (4.3)  
High (>20%) 2 (0.1) 17 (0.6)  
Results are expressed as mean (5 – 95th percentile) for risks and as number of subjects 
and (percentage) or mean ± standard deviation for the other variables. SBP, systolic 
blood pressure; DBP, diastolic blood pressure; HDL, high density cholesterol. Statistical 
analysis by chi-square, Student’s t-test or Mann-Whitney test (for risks): NS, not 
significant; ***, p<0.001. 
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Table II: predicted number of CHD events after 10 years according to the original and 
recalibrated Framingham risk function, compared to those estimated using mortality + 
case-fatality rates or incidence rates (men only), by age group and gender. 
 
 Framingham 
original 
Framingham 
recalibrated 
Mortality + 
case-fatality 
MONICA 
incidence rates 
Women     
35 – 44 (854) 4 (1 – 10) 2 (0 – 4) 1 – 2  
45 – 54 (880) 11 (2 – 34) 5 (1 – 15) 4 – 7  
55 – 34 (887) 22 (5 – 63) 10 (2 – 28) 7 – 12  
65 – 74 (453) 18 (5 – 43) 8 (2 – 19) 20 – 35  
All (3,074) 54 (13 – 151) 24 (5 – 66) 32 – 55  
Men     
35 – 44 (867) 27 (6 – 70) 13 (3 – 33) 5 – 8 4 – 8 
45 – 54 (808) 44 (12 – 101) 21 (6 – 49) 15 – 26 13 – 18 
55 – 34 (671) 67 (21 – 158) 32 (10 – 79) 29 – 50 19 – 25 
65 – 74 (353) 53 (16 – 119) 26 (8 – 62) 34 – 58 14 – 18 
All (2,699) 191 (55 – 449) 92 (26 – 223) 83 – 142 51 – 68 
 
Results expressed as mean and (5 – 95th percentile) for the original and recalibrated 
Framingham risk function and as range for the mortality + case-fatality rates. Incidence 
rates were available for men only; the first value corresponds to incidence rates from the 
cantons Vaud + Fribourg, the second from the canton Tessin. 
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Table III: sensitivity analysis for the recalibrated Framingham risk function, by gender and age group. 
  Mortality    
 2003 rates 2003 + 10% 2003 + 25% 2003 + 50% 2003 + 75% 
Recalibrated 
Framingham 
Men       
35-44 years 3.1 3.4 3.9 4.7 5.5 12.7 
45-54 years 10.0 11.0 12.5 15.1 17.6 21.1 
55-64 years 19.6 21.6 24.5 29.4 34.2 32.3 
65-74 years 22.5 24.8 28.1 33.7 39.3 26.2 
All 55.3 60.8 69.1 82.8 96.6 92.3 
W  omen       
35-44 years 0.6 0.7 0.8 0.9 1.1 1.5 
45-54 years 2.6 2.8 3.2 3.9 4.5 4.7 
55-64 years 4.8 5.3 6.0 7.2 8.4 9.7 
65-74 years 13.5 14.8 16.8 20.2 23.5 7.9 
All 21.5 23.6 26.9 32.2 37.6 23.8 
  Case-fatality    
 5% 10% 15% 20% 25% 
Recalibrated 
Framingham 
Men
omen
       
35-44 years 11.3 5.6 3.8 2.8 2.3 12.7 
45-54 years 36.1 18.1 12.0 9.0 7.2 21.1 
55-64 years 70.5 35.3 23.5 17.6 14.1 32.3 
65-74 years 81.1 40.6 27.0 20.3 16.2 26.2 
All 199.1 99.6 66.4 49.8 39.8 92.3 
W        
35-44 years 2.3 1.1 0.8 0.6 0.5 1.5 
45-54 years 9.3 4.7 3.1 2.3 1.9 4.7 
55-64 years 17.4 8.7 5.8 4.3 3.5 9.7 
65-74 years 48.4 24.2 16.1 12.1 9.7 7.9 
All 77.4 38.7 25.8 19.3 15.5 23.8 
Marques-Vidal P, Rodondi N, Bochud M, Chiolero A, Pécoud A, Hayoz D, Paccaud F, Mooser V, Firmann M, Waeber G, Vollenweider P. Predictive accuracy of original and recalibrated Framingham risk 
score in the Swiss population. International journal of cardiology 2009; 133(3):346-53 
Results are expressed in number of CHD events at 10 years according to mortality and case-fatality rates used. The upper part of the 
table uses a constant case-fatality rate of 18% with increasing CHD mortality rates starting from the original 2003 gender and age-
specific rates. The lower part of the tables uses the original 2003 gender and age-specific CHD mortality rates with varying levels of case-
fatality rates. The last column indicates the number of CHD events as predicted by the recalibrated Framingham risk function. 
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FIGURE LEGENDS 
Figure 1: expected number of CHD events after 10 years in the CoLaus study according 
to the original and recalibrated Framingham risk function, compared with results 
from mortality + case-fatality or from incidence rates (men only). 
Marques-Vidal P, Rodondi N, Bochud M, Chiolero A, Pécoud A, Hayoz D, Paccaud F, Mooser V, Firmann M, Waeber G, 
Vollenweider P. Predictive accuracy of original and recalibrated Framingham risk score in the Swiss population. International 
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Figure 1: Women 
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